Advanced Hematology Oncology PDX Tumor Biology Platforms for Drug Advancement

Logo
Presented by

Neal Goodwin, PhD, Vice President of Research Development

About this talk

Champions Oncology has established an advanced PDX platform for modeling hematology oncology malignancies, including AML and ALL. The resource consists of leukaphresis AML and ALL clinical patient samples that are characterized for the ability to engraft into P1 study mice. Additionally a resource for modeling define patient populations as they progress co-clinically has been created by collecting blasts from patients as they progress in the clinic. Both approaches are advantageous with the leukaphresis resource allowing for modeling large numbers of study mice across an established panel of patient samples and the co-clinical resource for modeling defined patient cohorts co-clinically.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (50)
Subscribers (2622)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.